Kamada Ltd. announced the commercial launch of two new biosimilar products in Israel: Ustekinumab-Kamada (a biosimilar to Stelara) and Enoxaparin-Kamada (a biosimilar to Clexane). These additions bring Kamada's total marketed biosimilars in the region to four, joining Bevacizumab-Kamada and Pegfilgrastim-Kamada. The company expects its existing commercial portfolio of biosimilars to generate approximately $4 million in sales in 2026, growing to roughly $10 million by 2028. By 2030, Kamada anticipates having at least 12 marketed biosimilar products licensed from six international partners, aiming for annual revenue between $20 million and $25 million. The company also expects the commercial availability of at least two additional biosimilar products during 2027. All four launched products are approved as interchangeable with their reference biologics. Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies and rare disease treatments.
